Hepatitis E Virus, IgM BioAssay(TM) ELISA Kit (HEV)

Hepatitis resulting from infection with viruses other than Hepatitis A Virus (HAV) and Hepatitis B (HBV) virus was previously referred to as non-A, non-B hepatitis. The first characterized non-A, non-B hepatitis agent was that responsible for parentally transmitted non-A, non-B hepatitis, or what is now called Hepatitis C Virus. This was followed by the cloning of a portion of the fecal-orally-transmitted agent, the Hepatitis E Virus (HEV).\nHepatitis E Virus has been referred to as enterically transmitted non-A, non-B hepatitis. Epidemics of enterically transmitted Hepatitis E Virus have been recognized worldwide but occur principally in developing countries. They have been reported in Southeast Asia, central Asia, Africa, Mexico, and Central America. In these areas, contaminated water has been implicated as the principal vehicle of virus transmission. Although HEV and HAV are transmitted in a similar manner, there are major differences in the clinical, pathological, and epidemiological courses of these two viruses. In particular, the mortality rate for HEV infection is 1 to 2%, or approximately 10-fold greater than that seen for HAV. Infection with HEV is particularly fatal for pregnant women, for whom the mortality rate can be as high as 10 to 20%.\n\nKit Components:\n1. H1927-04A: Microtiter Plate, 1x96 wells\n2. H1927-04B: Pab (HRP), 1x12ml\n3. H1927-04C: Non-Reactive Control, 1x1ml\n4. H1927-04D: Reactive Control, 1x1ml\n5. H1927-04E: Sample Diluent, 1x60ml\n6. H1927-04F: Wash Buffer, 20x, 1x60ml\n7. H1927-04G: Substrate A, 1x10ml\n8. H1927-04H: Substrate B, 1x0ml\n9. H1927-04J: Stop Solution, 1x14ml, 2N sulfuric acid (H2SO4). \n\nStorage and Stability:\nStore other components at 4 degrees C. Stable for 6 months For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

H1927-04

Size

96Tests

Applications

ELISA

Reactivities

Hum

References

1. Aggarwal R, Krawczynski K. Hepatitis E: an overview and recent advances in clinical and laboratory research. J. Gastroenterol Hepatol 2000 Jan; 15(1): 9-20. 2. Ruan B, Zhuang H, Ma Y. Dynamics of anti-HEV ORF2, ORT3, IgM and IgG in serial sera of patients with hepatitis E and their clinical significance. Chung Hua I Hsueh Tsa Chih 1998 Jul; 78(7): 498-500. 3. Riddell MA, Li F, Anderson DA. Identification of immunodominant and conformational epitopes in the capsid protein of hepatitis E virus by using monoclonal antibodies. J. Viral 2000 Sep; 74(7): 8011-7. 4. Krawczynski K, Aggarwal R, Kamili S. Hepatitis E. Infect. Dis. Clin. North Am. 2000 Sep; 14(3): 669-87. 5. Li TC, Shinzawa H, etc. Empty virus-like particle-based enzyme-linked immunosorbent assay for antibodies to hepatitis E virus. J Med Virol 2000 Nov; 62(3): 327-33.